Is This Biotech Stock Worth the Trouble?
23/4 17:00
Biotech giant Biogen (NASDAQ: BIIB) has had its share of ups and downs in the past couple of years. Many of the headlines the company generated were related to the controversial approval of its Alzheimer's disease (AD) drug Aduhelm....